DelveInsight’s Cutaneous T-cell Lymphoma (CTCL) Market Insights report includes a comprehensive understanding of current treatment practices, cutaneous T-cell lymphoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan].
Cutaneous T-cell Lymphoma Overview
Cutaneous T-cell lymphoma (CTCL) is a group of diseases characterized by an abnormal accumulation of malignant T-cells in the skin, which can lead to the formation of rashes, plaques, and tumors. Furthermore, CTCLs account for more than three out of every four skin lymphomas diagnosed, and they frequently manifest as eczema-like skin rashes and can affect multiple body parts. The exact cutaneous T-cell lymphoma causes are still not known.
Cutaneous T-cell lymphoma symptoms include skin patches and lumps, enlarged lymph nodes, hair loss, thickening of the skin on the palms of the hands and soles of the feet, and rash-like skin redness that is intensely itchy all over the body.
A thorough clinical evaluation, detection of specific CTCL symptoms and physical findings, a detailed patient history, and a variety of specialized tests are used for cutaneous T-cell lymphoma diagnosis.
Key Takeaways from the Cutaneous T-cell Lymphoma Market Report
- As per DelveInsight analysis, the cutaneous T-cell lymphoma market size in the 7MM was valued at approximately USD 399 million in 2021.
- As per the estimates, the total cutaneous T-cell lymphoma incident population in the 7MM was around 7,485 in 2021.
- Leading cutaneous T-cell lymphoma companies such as Pfizer, Eisai, Citius Pharmaceuticals, Bristol Myers Squibb, Merck, Kyowa Kirin, Medivir, Seagen, Soligenix, 4SC AG, Galderma, Equillium, Innate Pharma, BeiGene, Codiak BioSciences, Astex Pharmaceuticals, and others are developing novel cutaneous T-cell lymphoma drugs that can be available in the cutaneous T-cell lymphoma market in the upcoming years.
- The cutaneous T-cell lymphoma therapies in the pipeline include SGX301, Pembrolizumab, Resminostat, CD11301, EQ101, Tolinapant (ASTX660), exoIL-12, Lacutamab, Remetinostat, Resminostat, Tislelizumab (BGB-A317), and others.
- Compared to other indications, CTCL has a good prognosis, which prevents treatment-related toxicity. There are many established patient advocacy groups and international collaborations for this indication.
Discover which therapies are expected to grab major cutaneous T-cell lymphoma market share @ Cutaneous T-cell Lymphoma Market Report
Cutaneous T-cell Lymphoma Epidemiology Segmentation
- As per our analysis, there were around 7,485 cutaneous T-cell lymphoma incident cases in the 7MM in 2021.
- Among the EU5 countries, Germany had the highest incidence of CTCL in 2021.
The cutaneous T-cell lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Incident Population of CTCL
- Type-specific Cases of CTCL
- Sub-type specific incidence of CTCL
- Gender-specific cases of CTCL
- Stage-specific cases of CTCL
- Treatment-eligible incident population in early-and advanced-stage
Cutaneous T-cell Lymphoma Treatment Market
A patient’s CTCL treatment plan is determined by several factors, including the person’s overall health, age, and disease stage. The type and extent of skin lesions (patches, plaques, or tumors), the number of Sézary cells in the blood, and transformation to large cell type or folliculotropic cancer (involving the hair follicles) all influence cutaneous T-cell lymphoma treatment options.
Patients with early-stage mycosis fungoides or Sézary syndrome may respond well to skin-directed therapies alone. In contrast, patients with advanced disease may require a combination of topical and systemic therapies (affecting the entire body). ISTODAX (romidepsin), VALCHLOR (mechlorethamine), UVADEX (methoxsalen), TARGRETIN (bexarotene), ADCETRIS (brentuximab vedotin), POTELIGEO (mogamulizumab), and ZOLINZA (vorinostat) are some of the FDA-approved drugs.
To know more about cutaneous T-cell lymphoma treatment options, visit @ New Treatment for Cutaneous T-cell Lymphoma
Cutaneous T-cell Lymphoma Pipeline Therapies and Key Companies
- SGX301: Soligenix
- Pembrolizumab: Merck
- Resminostat: 4SC AG
- CD11301: Galderma
- EQ101: Equillium
Scope of the Cutaneous T-cell Lymphoma Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Cutaneous T-cell Lymphoma Companies: Pfizer, Eisai, Citius Pharmaceuticals, Bristol Myers Squibb, Merck, Kyowa Kirin, Medivir, Wellness Pharma, Seagen, Soligenix, 4SC AG, Galderma, Equillium, and others
- Key Cutaneous T-cell Lymphoma Therapies: SGX301, Pembrolizumab, Resminostat, CD11301, EQ101, and others
- Cutaneous T-cell Lymphoma Therapeutic Assessment: Cutaneous T-cell Lymphoma current marketed and emerging therapies
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Cutaneous T-cell Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Cutaneous T-cell Lymphoma Market Access and Reimbursement
Discover more about drugs for cutaneous T-cell lymphoma in development @ CTCL Clinical Trials
Table of Contents
|
1 |
Key Insights |
|
2 |
Report Introduction |
|
3 |
Executive Summary |
|
4 |
Key Events |
|
5 |
SWOT Analysis |
|
6 |
Epidemiology and Market Methodology |
|
7 |
CTCL Market Overview at a Glance |
|
7.1 |
Market Share (%) Distribution by Therapies in 2021 |
|
7.2 |
Market Share (%) Distribution by Therapies in 2032 |
|
8 |
Disease Background and Overview |
|
8.1 |
Introduction |
|
8.2 |
Classification |
|
8.3 |
Symptoms |
|
8.4 |
Etiopathogenesis |
|
8.5 |
Genomic Landscape of SS/MF |
|
8.6 |
Biomarkers |
|
8.7 |
Diagnosis |
|
8.8 |
Staging and Assessment |
|
9 |
Treatment and Management of CTCL |
|
10 |
Treatment Guidelines |
|
11 |
Epidemiology and Patient Population of CTCL in the 7MM |
|
11.1 |
Key Findings |
|
11.1.1 |
Assumptions and Rationale |
|
11.1.1.1 |
United States |
|
11.1.2.1 |
The EU5 |
|
11.1.3.3 |
Japan |
|
11.2 |
Total Incident Population of CTCL in the 7MM |
|
11.3 |
The United States |
|
11.3.1 |
Total Incident Population of CTCL in the United States |
|
11.3.2 |
Type-specific Cases of CTCL in the United States |
|
11.3.3 |
Subtype-specific Cases of MF in the United States |
|
11.3.4 |
Gender-specific CTCL cases in the United States |
|
11.3.5 |
Stage-specific Cases of CTCL in the United States |
|
11.3.6 |
Treatment-eligible Incident Population in Early-and Advanced-stages in the United States |
|
11.4 |
The EU5 |
|
11.4.1 |
Total Incident Population of CTCL in the EU5 |
|
11.4.2 |
Type-specific Cases of CTCL in the EU5 |
|
11.4.3 |
Subtype-specific Cases of MF in the EU5 |
|
11.4.4 |
Gender-specific CTCL Cases in the EU5 |
|
11.4.5 |
Stage-specific Cases of CTCL in the EU5 |
|
11.4.6 |
Treatment-eligible Incident Population in Early-and Advanced-stages in the EU5 |
|
11.5 |
Japan |
|
11.5.1 |
Total Incident Population of CTCL in Japan |
|
11.5.2 |
Type-specific Cases of CTCL in Japan |
|
11.5.3 |
Subtype-specific Cases of MF in Japan |
|
11.5.4 |
Gender-specific CTCL cases in Japan |
|
11.5.5 |
Stage-specific Cases of CTCL in Japan |
|
11.5.6 |
Treatment-eligible Incident Population in Early-and Advanced-stages in Japan |
|
12 |
Patient Journey |
|
13 |
Key Endpoints in CTCL |
|
14 |
Marketed Drugs |
|
14.1 |
Key Competitors |
|
15 |
Emerging Drugs |
|
15.1 |
Key Competitors |
|
16 |
CTCL: 7MM Market Analysis |
|
16.1 |
Key Findings |
|
16.2 |
Market Outlook |
|
16.3 |
Attribute Analysis |
|
16.4 |
Key Market Forecast Assumptions |
|
16.5 |
Total Market Size of CTCL in the 7MM |
|
16.6 |
The United States Market Size |
|
16.6.1 |
Total Market Size of CTCL in the United States |
|
16.6.2 |
Market Size of Early-stage CTCL by Therapies in First Line in the United States |
|
16.6.3 |
Market Size of Early-stage CTCL by Therapies in Second Line in the United States |
|
16.6.4 |
Market Size of Advanced-stage CTCL by Therapies in First Line in the United States |
|
16.6.5 |
Market Size of Advanced-stage CTCL by Therapies in Second Line in the United States |
|
16.7 |
The EU-5 Market Size |
|
16.7.1 |
Total Market size of CTCL in the EU5 |
|
16.7.2 |
Market Size of Early-stage CTCL by Therapies in First Line in the EU5 |
|
16.7.3 |
Market Size of Early-stage CTCL by Therapies in Second Line in the EU5 |
|
16.7.4 |
Market Size of Advanced-stage CTCL by Therapies in First Line in the EU5 |
|
16.7.5 |
Market Size of Advanced-stage CTCL by Therapies in Second Line in the EU5 |
|
16.8 |
Japan |
|
16.8.1 |
Total Market size of CTCL in Japan |
|
16.8.2 |
Market Size of Early-stage CTCL by Therapies in First Line in Japan |
|
16.8.3 |
Market Size of Early-stage CTCL by Therapies in Second Line in Japan |
|
16.8.4 |
Market Size of Advanced-stage CTCL by Therapies in First Line in Japan |
|
16.8.5 |
Market Size of Advanced-stage CTCL by Therapies in Second Line in Japan |
|
17 |
Unmet Needs |
|
18 |
Market Access and Reimbursement |
|
18.1 |
US |
|
18.2 |
Europe |
|
18.3 |
Japan |
|
19 |
Appendix |
|
19.1 |
Bibliography |
|
19.2 |
Report Methodology |
|
20 |
DelveInsight Capabilities |
|
21 |
Disclaimer |
|
22 |
About DelveInsight |
Learn more about the cutaneous T-cell lymphoma therapies in clinical trials @ Drugs for CTCL Treatment
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting